ACS: Contralateral Prophylactic Mastectomy May Not Extend Survival

Share this content:
ACS: Contralateral Prophylactic Mastectomy May Not Extend Life
ACS: Contralateral Prophylactic Mastectomy May Not Extend Life

(HealthDay News) -- A decision model shows that women with early breast cancer without a BRCA mutation who undergo contralateral prophylactic mastectomy (CPM) have a maximum gain in life expectancy of about 6 months, according to a study presented at the annual meeting of the American College of Surgeons, held from Oct. 6 to 10 in Washington, D.C.

Pamela Rochelle Portschy, M.D., of the University of Minnesota in Minneapolis, and colleagues developed a decision-analytic Markov model to assess the effect of CPM on life expectancy in women with early breast cancer without a BRCA mutation.

The researchers found that gains in life expectancy for women undergoing CPM ranged from 0.12 to 0.52 years for stage I breast cancer and 0.08 to 0.31 years for stage II breast cancer. Greater benefit of CPM was observed in younger women and those with stage I and estrogen receptor negative disease.

"I think this decision model study will provide women who are considering these extensive operations with more accurate information about whether or not CPM is going to improve their survival," a coauthor said in a statement.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs